Nurix Therapeutics (NRIX) H.C. Wainwright 27th Annual Global Investment Conference summary

Advances in targeted protein degradation

• Targeted protein degraders offer oral, once-daily dosing and can remove entire proteins, including resistant mutants, providing advantages over antibodies and nucleic acid-based therapies.

• The pipeline includes oncology and immunology assets, with Bexabrutadeg (NX-5948) entering pivotal trials and other compounds like Zelbrutamide and NX-1607 advancing in development.

• Collaborations with Sanofi and Gilead have resulted in significant investments and progress in STAT6 and IRAK4 degrader programs, now moving into clinical studies.

Clinical efficacy and development plans

• Bexabrutadeg degrades both wild-type and inhibitor-resistant BTK, showing high potency and complete BTK degradation in patients regardless of mutation status.

• Clinical data show an 81% objective response rate, with durable responses and a favorable safety profile; pivotal single-arm and confirmatory randomized trials are planned.

• The phase 3 program targets second-line CLL, addressing a significant market, with additional trials in Waldenstrom's and non-Hodgkin's lymphoma showing high response rates.

Competitive landscape and differentiation

• Bexabrutadeg is differentiated by its ability to degrade BTK, including kinase-dead and resistant mutants, outperforming both covalent and non-covalent inhibitors.

• Early data suggest potential selectivity and safety advantages over competitors like BGB-16673 and ABBV-101, with a large and growing market for BTK-targeted therapies.

• The confirmatory phase 3 trial uses a globally relevant control arm and is designed to address regulatory requirements across geographies.